TRMED Stock Overview
Thor Medical ASA produces and supplies alpha-particle emitters for cancer therapy in Norway.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Thor Medical ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr1.06 |
| 52 Week High | kr2.30 |
| 52 Week Low | kr0.85 |
| Beta | 0 |
| 1 Month Change | 2.91% |
| 3 Month Change | -11.37% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -46.95% |
Recent News & Updates
Recent updates
Shareholder Returns
| TRMED | NO Biotechs | NO Market | |
|---|---|---|---|
| 7D | -0.6% | 0.01% | 0.9% |
| 1Y | n/a | -66.4% | 4.6% |
Return vs Industry: Insufficient data to determine how TRMED performed against the Norwegian Biotechs industry.
Return vs Market: Insufficient data to determine how TRMED performed against the Norwegian Market.
Price Volatility
| TRMED volatility | |
|---|---|
| TRMED Average Weekly Movement | 10.1% |
| Biotechs Industry Average Movement | 10.1% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in NO Market | 10.5% |
| 10% least volatile stocks in NO Market | 2.9% |
Stable Share Price: TRMED has not had significant price volatility in the past 3 months.
Volatility Over Time: TRMED's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Norwegian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 2 | Alf Bjørseth | www.thormedical.no |
Thor Medical ASA produces and supplies alpha-particle emitters for cancer therapy in Norway. It develops Ra224, an isotope of radium; Pb-212, a radioactive isotope of lead; and Th-228, a radioactive isotope of thorium. The company was founded in 2009 and is headquartered in Oslo, Norway.
Thor Medical ASA Fundamentals Summary
| TRMED fundamental statistics | |
|---|---|
| Market cap | kr248.95m |
| Earnings (TTM) | -kr5.56m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-44.8x
P/E RatioIs TRMED overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TRMED income statement (TTM) | |
|---|---|
| Revenue | kr0 |
| Cost of Revenue | kr0 |
| Gross Profit | kr0 |
| Other Expenses | kr5.56m |
| Earnings | -kr5.56m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Aug 30, 2024
| Earnings per share (EPS) | -0.024 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did TRMED perform over the long term?
See historical performance and comparison